Sextant Therapeutics, Inc. has developed a proprietary technology for pre-clinical research that vastly improves our understanding of how chemotherapy fights cancer and will allow us to develop more effective combinations of existing chemotherapeutic agents to fight the most deadly cancers. This platform technology enables the development of clinical diagnostics that will evaluate which chemotherapies will be most effective in treating a given cancer. And, with our technology, we will be able to develop an entirely new class of chemotherapy drugs that will directly recruit a patient’s immune responses to eliminate cancer. Sextant’s products will not only streamline the cancer diagnosis and treatment process but also reduce expensive hospital and laboratory costs. Sextant’s technology will help save lives by defining the best direction for cancer therapy.
A Pre-clinical Revolution
For the first time, we can accurately mimic drug treatment in the clinic – acute therapeutic intervention to treat actively growing tumors – in pre-clinical models, creating a far more accurate model of how human disease is treated. Our proprietary proteomic Profiling technology combined with our patented genetic Modeling technology provide unprecedented detail and precision. Our iterative Profiling and Modeling approach gives us the power to pick apart biological systems to discover HOW drugs work, and how genes influences drug efficacy.
We have developed an integrated platform drug discovery technology that offers faster, more robust research solutions to analyze tumor signaling and responses to chemotherapy. Our revolutionary research technology enables us to:
- Significantly reduce the time required to determine how a tumor responds to drug treatment and if a candidate drug hits its target
- Extract critical information from pre-clinical models to more accurately assess whether a drug should move to clinical trials
- Dramatically increase the quality and quantity of crucial information defining a tumor’s response to chemotherapy
- Rapidly identify high value targets for development of companion diagnostics